Akebia Therapeutics $140M Debt Financing with Symbiotic Capital Opportunities Holding, L.P.
Akebia Therapeutics entered into a $140 million senior secured term loan facility with Symbiotic Capital, consisting of a $60 million initial tranche and $80 million in discretionary tranches. The company used the initial proceeds to repay its existing $55 million debt facility with BlackRock (Kreos). The new facility features a 60-month interest-only period with a maturity date of November 12, 2031.
Akebia Therapeutics continues to face significant financial risks, including a history of losses and the need for substantial additional capital to fund operations. The company's business remains heavily dependent on the commercial success of Auryxia and Vafseo, while facing potential delisting from Nasdaq if compliance requirements are not met.
Akebia Therapeutics reported Q3 2026 financial results, highlighted by a 140% year-over-year increase in patients on Vafseo to approximately 11,500. The company reported Vafseo net product revenues of $14.8 million and maintained a strong cash position of $159.3 million as it prepares for expanded market access in 2027.
Term
Q3 2026
“Our strategic commercial priority remains making Vafseo standard of care for the treatment of anemia for patients on dialysis, and we are focused on continuing to increase the number of patients on therapy.”
John P. Butler, Chief Executive Officer of Akebia
“We believe this compelling data has the potential to drive Vafseo to be standard of care. We continue to work to strengthen our market position as we enter 2027 when we believe Vafseo access will expand beyond the Transitional Drug Add-on Payment Adjustment (TDAPA)-only patients to nearly all clinically eligible patients.”
Akebia Therapeutics received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 19, 2027, to regain compliance, which requires the stock to close at $1.00 or higher for at least 10 consecutive business days. Akebia is evaluating options to cure the deficiency, including a potential reverse stock split.
Nicholas Grund, Senior Vice President and Chief Commercial Officer, notified Akebia Therapeutics of his resignation effective November 6, 2026, for personal reasons. Following his departure, Mr. Grund will provide consulting and advisory services to the company through April 30, 2027, under a newly established consulting agreement.